As the pandemic continues, the US Food and Drug Administration will rely selectively on virtual site visits to help it make timely approval and licensing decisions, though usually not to confirm post-warning letter corrective actions, the agency said 14 April in eagerly awaited guidance on what are generically called virtual inspections, but which it terms “remote interactive evaluations.”
The ability to make decisions based on remote interactive evaluations is an important tool that counterparts like the European Medicines...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?